Abstract: A kit for determining whether a patient will develop severe dengue includes a binding partner for platelet factor 4 and a binding partner for at least one member selected from the group consisting of dengue virus NS1 protein, olfactomedin 4, and ?2-macroglobulin. The kit may further include a label reagent capable of generating a detectable signal.

Abstract: A kit for determining whether a patient will develop severe dengue includes a binding partner for olfactomedin 4 and a binding partner for at least one member selected from the group consisting of dengue virus NS1 protein, platelet factor 4, and ?2-macroglobulin. The kit may further include a label reagent capable of generating a detectable signal.

Abstract: A kit for determining whether a patient will develop severe dengue includes a binding partner for olfactomedin 4 and a binding partner for at least one member selected from the group consisting of dengue virus NS1 protein, platelet factor 4, and ?2-macroglobulin. The kit may further include a label reagent capable of generating a detectable signal.

Abstract: A kit for determining whether a patient will develop severe dengue includes a binding partner for platelet factor 4 and a binding partner for at least one member selected from the group consisting of dengue virus NS1 protein, olfactomedin 4, and ?2-macroglobulin. The kit may further include a label reagent capable of generating a detectable signal.

Abstract: A method for determining, in vitro, the probability of a patient developing severe dengue, based on a blood sample, in which: a) the quantity in the blood sample of at least one marker, which is platelet factor 4, is determined; b) the quantity of platelet factor 4 determined in step a) is compared with a reference quantity of the marker obtained from a group of individuals who have been diagnosed with non-severe dengue, wherein, if the quantity of platelet factor 4 determined in step a) is less than the reference quantity established in step b), it is determined that the patient will develop severe dengue.

Abstract: A method for determining, in vitro, the probability of a patient developing severe dengue, based on a blood sample, according to a) the quantity in the blood sample of at least one marker, which is olfactomedin 4, is determined, b) the quantity of olfactomedin 4 determined in step a) is compared with a reference quantity of the marker obtained from a group of individuals who have been diagnosed with non-severe dengue, wherein, if the quantity of olfactomedin 4 determined in step a) is greater than the reference quantity established in step b), it is determined that the patient will develop severe dengue.

Abstract: A method for determining, in vitro, the probability of a patient developing severe dengue, based on a blood sample, according to a) the quantity in the blood sample of at least one marker, which is olfactomedin 4, is determined, b) the quantity of olfactomedin 4 determined in step a) is compared with a reference quantity of the marker obtained from a group of individuals who have been diagnosed with non-severe dengue, wherein, if the quantity of olfactomedin 4 determined in step a) is greater than the reference quantity established in step b), it is determined that the patient will develop severe dengue.

Abstract: A method for determining, in vitro, the probability of a patient developing severe dengue, based on a blood sample, in which: a) the quantity in the blood sample of at least one marker, which is platelet factor 4, is determined; b) the quantity of platelet factor 4 determined in step a) is compared with a reference quantity of the marker obtained from a group of individuals who have been diagnosed with non-severe dengue, wherein, if the quantity of platelet factor 4 determined in step a) is less than the reference quantity established in step b), it is determined that the patient will develop severe dengue.